Glenmark soars on getting certificate of compliance from European regulator for Baddi manufacturing unit

16 Dec 2019 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 345.00, up by 5.30 points or 1.56% from its previous closing of Rs. 339.70 on the BSE.

The scrip opened at Rs. 336.40 and has touched a high and low of Rs. 350.00 and Rs. 336.40 respectively. So far 84561 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 706.90 on 31-Dec-2018 and a 52 week low of Rs. 267.30 on 14-Nov-2019.

Last one week high and low of the scrip stood at Rs. 350.00 and Rs. 322.70 respectively. The current market cap of the company is Rs. 9788.41 crore.

The promoters holding in the company stood at 46.58%, while Institutions and Non-Institutions held 38.80% and 14.62% respectively.

Glenmark Pharmaceuticals has received certificate of compliance for Baddi manufacturing facility from European regulator, SUKL (State Institute for Drug control), Czech Republic. This certificate complies with the principles and guidelines of good manufacturing practice laid down in the directive 2003/94/EC which stipulates the requirements to fulfil GMP recommendations of WHO.

Baddi manufacturing unit of the company was inspected by the leading European regulator, SUKL, Czech Republic in the week of October 21, 2019.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).


Glenmark Pharma Share Price

1120.00 -55.40 (-4.71%)
04-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1455.00
Dr. Reddys Lab 5730.85
Cipla 1459.75
Zydus Lifesciences 1007.20
Lupin 1564.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.